Blood and Blood Components Market Size and Share Analysis - 2026 To 2033
The Blood and Blood Components Market size is anticipated to grow at a CAGR of 4.7% with USD 51.3 Bn in 2026 and is expected to reach USD 70.8 Bn in 2033. The market growth is primarily driven by the increasing prevalence of chronic diseases, rising number of surgical procedures and trauma cases, growing demand for blood transfusions, and expanding healthcare infrastructure across developing economies. According to the World Health Organization (WHO) Global Status Report on Blood Safety and Availability 2025, about 120.4 million units of blood were donated worldwide, out of which more than 85% were from voluntary non-remunerated donors.
Key Takeaways
- Blood Components segment is likely to dominate the market with 81.5% in 2026. This segment is expected to grow due to the rising popularity of component therapy, where patients can receive specific blood components such as red blood cells, plasma, platelets, and white blood cells according to their needs. As stated in the WHO Fact sheet on Blood Safety and Availability in 2026, 98% of blood collected in high-income countries and 94% in upper-middle-income countries undergo processing into blood components.
- Trauma and Surgery segment will be ahead by 34.2% in 2026. This growth of the segment will be due to the growing number of trauma patients, complicated surgeries, organ transplants, and accidents, which result in hospitalization and need for massive blood transfusion. According to WHO statistics, about 1.19 million people die every year from road traffic accidents, while many more sustain injuries requiring blood transfusion.
- Hospitals segment is likely to dominate the market with 67.4% in 2026. The segment’s growth is owing to the high volume of inpatient procedures, emergency care services, intensive care treatments, and specialized surgeries performed in hospital settings.
- According to the WHO's 2025 report on blood safety, hospitals continue to be the major hubs of blood usage across the world, where most of the blood and blood components are transfused every year.
- North America is anticipated to hold the major market share of the Blood and Blood Components Market by 2026 and will account for around 39.8% of the global market share. North America’s dominance in the market is attributed to the well-structured blood collection infrastructure in the region, huge investment in healthcare sector, modern practices of transfusion medicine, extensive availability of blood banks, and rising demand for blood-based treatments. As per, the blood donation rate in developed countries stands at 28.9 per 1,000 population, whereas in developing countries, it stands at 8.5 per 1,000 population.
Segmental Insights
Why do Blood Components Hold the Largest Market Share?
On the basis of product type, the Blood Components segment is projected to account for the largest Blood and Blood Components Market share of 81.5% in 2026 The expansion of this sector is attributed to the extensive use of component therapy, which allows healthcare professionals to provide red blood cells, plasma, platelets, and white blood cells on a patient-specific basis, thus maximizing the use of blood.
According to the WHO Blood Safety and Availability Fact Sheet (June 2026), approximately 21.5 million litres of plasma from 36 reporting countries were fractionated for the production of plasma-derived medicinal products during the reporting year, including around 27% of plasma recovered from whole blood donations.
In March 2025, Grifols completed the acquisition of 14 U.S. plasma donation centers from Immunotek, expanding its vertically integrated plasma collection network.
- Current Industry Events of 2026
- Market Size Estimation
- Regional Breakdown
- Competitive Landscape
- Customer Intelligence
- Segmental Analysis
- Pricing Analysis
- Key Market Drivers, Challenges & Future Trends
- Customized Insights Section
Trauma and Surgery Hold the Largest Market Share
On the basis of application, the Trauma and Surgery segment is projected to lead with a 34.2% share in 2026. The segment’s growth is owing to the increasing number of emergency trauma cases, major surgical procedures, organ transplantations, and accident-related hospitalizations requiring significant blood transfusion support.
According to the Global Guidelines for Intraoperative Blood Management (2024), it is projected that there are about 313 million surgeries conducted annually around the world, and 4.2 million people (7.7%) lose their lives within the first 30 days of their surgical procedures.
In April 2025, Baxter International announced the launch of the room temperature variant of HEMOPATCH Sealing Hemostat in Europe. This collagen-based sealing hemostat helps in controlling the flow of blood and minimizes fluid loss during surgery while providing easier storage and quick availability in the operating theater.
Why do Hospitals Hold the Largest Market Share?
On the basis of end user, the Hospitals segment is projected to account for the largest Blood and Blood Components Market share of 67.4% in 2026. The segment’s growth is owing to the high volume of inpatient procedures, emergency care services, intensive care treatments, trauma management, and specialized surgeries performed in hospital settings, making hospitals the primary consumers of blood and blood components.
According to the World Health Organization (WHO) Blood Safety and Availability Fact Sheet (updated June 2026), only 40% of hospitals performing blood transfusions have hospital transfusion committees, while 68% have systems for reporting adverse transfusion events.
In February 2025, Abbott highlighted the role of its Alinity i System in enhancing blood screening accuracy and efficiency for blood banks and laboratories.
Market Drivers
Rising Burden of Anemia and Blood Disorders is Driving Growth in the Blood and Blood Components Market
The increasing prevalence of anemia, hematological disorders, and chronic diseases is significantly driving demand for blood and blood components worldwide. Red blood cells, platelets, and plasma have wide applications in the treatment of anemia, leukemia, lymphoma, sickle cell anemia, thalassemia, and other diseases associated with the blood. The increasing number of patients requiring frequent blood transfusions has significantly increased the demand for blood components.
As per the WHO update of 2025, anemia affects about 40% of children between the ages of 6 and 59 months, 37% of pregnant women, and 30% of women between the ages of 15 and 49 years worldwide, thus ranking as one of the most common diseases needing treatment involving blood.
In October 2025, Terumo Blood and Cell Technologies announced a strategic investment in Hemex Health in order to increase the availability of diagnostic testing and patient care related to sickle cell disease and other hemoglobinopathies.
Growing Number of Surgeries and Trauma Cases Accelerating Demand for Blood Transfusions
The increased number of surgical cases, injuries, transplantation of organs, and emergencies is expected to drive the demand for blood and its components significantly. Contemporary healthcare depends heavily on red blood cells, plasma, and platelets to control blood loss associated with major surgeries and other treatments. Increased investment in the field of healthcare and access to surgical procedures will contribute further to the growth of the market.
According to the WHO estimate that more than 310 million major surgeries take place annually worldwide, showing the high requirements of blood products during such operations.
In March 2025, Octapharma announced positive Phase III FARES-II trial results demonstrating that its four-factor Prothrombin Complex Concentrate (4F-PCC) was superior to frozen plasma in managing excessive bleeding during cardiac surgery.
Current Events and Their Impact on the Blood and Blood Components Market
Current Event | Description and its Impact |
WHO Launches Global Initiative to Improve Anaemia Measurement and Diagnosis (February 2025) |
|
Terumo Blood and Cell Technologies Expands Automated Blood Component Processing (January 2025) |
|
Blood and Blood Components Market Trends
- The growing acceptance of Patient Blood Management (PBM) initiatives is ensuring optimal use of blood, minimizing blood wastage through unnecessary transfusions, and enhancing patient outcomes within hospitals. As per the WHO Global Status Report on Blood Safety and Availability 2025, there are 129 countries that have national guidelines for the safe and appropriate clinical use of blood.
- The digitalization of blood banks and transfusion services is also making it easier to trace blood products, manage inventories, and ensure the safety of transfusions. As noted in the World Health Organization Global Status Report on Blood Safety and Availability 2025, 79% of reporting countries have established systems for reporting adverse transfusion events.
- Increasing focus on voluntary non-rewarded blood donation makes the process more sustainable in the long run. As per the WHO Global Status Report on Blood Safety and Availability 2025, over 85% of all blood donations around the world come from voluntary non-rewarded donors, which shows improvement in terms of blood safety systems.
Regional Insights
North America Dominates Owing to Advanced Blood Collection Infrastructure and High Transfusion Demand
The North America region will hold a market share of 39.8% in 2026. The growth of the North America region is due to the established system of blood collection facilities, high healthcare costs, advanced transfusion medicine practices, high number of blood banks, and use of blood component therapy. The growing number of surgeries, trauma cases, transplantations, and plasma products are driving the market growth in the North America region.
Based on the World Health Organization (WHO) Fact Sheet on Blood Safety and Availability (updated June 2026), wealthy countries contribute about 36% of the total blood donations worldwide even though they make up merely 15% of the total population.
In June 2025, America's Blood Centers launched Blood Advocacy Week 2025 and brought over 100 organizations from the U.S. healthcare industry to persuade the Congress to improve America’s blood supply system.
Asia Pacific Blood and Blood Components Market Trends
Asia Pacific is anticipated to experience rapid growth in the market for Blood and Blood Components during the forecast period. This is attributed to factors such as improvement in healthcare facilities in the region, increase in awareness regarding voluntary blood donation, high prevalence of anemia and hematology disorders, growing number of surgeries and government efforts to develop national blood transfusion services in countries including China, India, Japan, and South Korea.
According to the World Health Organization Global Status Report on Blood Safety and Availability 2025 released in June 2026, the South-East Asia Region witnessed one of the highest achievements of voluntary, unpaid blood donation over the last ten years owing to enhanced national blood programs, donor mobilization, and quality management systems in the region’s countries.
In June 2025, the Ministry of Health and Family Welfare conducted a national survey of the status of blood transfusion services in all states and union territories, assessing the process of blood collection, testing, processing, storage, distribution, and reporting based on data available through eRaktKosh, BBMS, CDSCO, and state level regulatory agencies.
Advanced Blood Collection Infrastructure and Strong Voluntary Blood Donation Programs are Driving the Market in the United States
The U.S. Blood and Blood Components Market continues to grow due to the efficient blood collection infrastructure, superior transfusion medicine technology, rising number of surgeries, and widespread use of blood component therapy. Consistent development in blood safety, donor mobilization, and laboratory automation systems are helping enhance the existing blood supply chain in the country.
As per the data provided by the American Red Cross (2025), the organization provides roughly 40% of the total blood and blood components in the country. In addition, an average of almost 29,000 units of red blood cells, around 6,500 units of platelets, and roughly 5,000 units of plasma are required each day in the country.
In December 2025, Cerus Corporation announced a Group Purchasing Agreement (GPA) with Blood Centers of America, the largest blood supply cooperative in the United States.
China Blood and Blood Components Market Trends
The China Blood and Blood Components Market is driven by increasing healthcare expenditure, modernization of blood banks, increasing incidences of chronic diseases, and various government efforts aimed at encouraging voluntary blood donations. There are also increasing investments in blood components collection, automation of laboratories, and processing of blood components.
According to the National Health Commission (NHC) of China, released in June 2025, China's blood donation rate reached 11.4 donations per 1,000 population. The NHC also stated that the country has established a nationwide voluntary blood donation system, strengthened blood screening technologies, and implemented cross-regional blood allocation mechanisms to ensure a safe and stable blood supply.
Who are the Major Companies in Blood and Blood Components Industry
Some of the major key players in Blood and Blood Components Market are Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc.
Key News
- In March 2025, Beckman Coulter announced U.S. FDA clearance for the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system designed to improve laboratory efficiency and support high-quality diagnostic testing, including transfusion medicine and blood testing workflows.
- In February 2025, Bio-Rad Laboratories announced the launch of new quality control solutions for transfusion medicine and immunohematology laboratories, helping blood banks improve the accuracy and reliability of blood grouping and compatibility testing.
Market Report Scope
Blood and Blood Components Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 51.3 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.7% | 2033 Value Projection: | USD 70.8 Bn |
| Geographies covered: |
| ||
| Segments covered: |
| ||
| Companies covered: | Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc. | ||
| Growth Drivers: |
| ||
| Restraints & Challenges: |
| ||
Analyst Opinion
- The Blood and Blood Components Market is expected to benefit from continued government investment in national blood systems and transfusion safety. According to the WHO Global Status Report on Blood Safety and Availability 2025 (published June 2026), 79% (133 of 168) of reporting countries now have a national blood policy, while 71% have legislation specifically covering the safety and quality of blood transfusion, reflecting stronger regulatory support for blood services worldwide.
- The analysts forecast that the PDMPs segment will be one of the fastest-growing segments in the global market due to increased emphasis on self-sufficiency in the processing of plasma by various countries. As per the “WHO Fact Sheet on Blood Safety and Availability” released in June 2026, out of 168 countries that have provided information, only 49 manufacture PDMPs using domestically sourced plasma, whereas 119 countries are either fully dependent on imports or do not manufacture PDMPs at all.
- Analysts believe patient blood management (PBM), haemovigilance, and quality assurance programs will increasingly shape market growth over the coming years. According to the WHO Global Status Report on Blood Safety and Availability 2025, only 52% (88 of 168) of reporting countries have established national haemovigilance systems, indicating substantial opportunities for investments in transfusion monitoring, blood safety technologies, digital blood bank management, and quality improvement programs.
Speak to the analyst
Want personalized insights?
Take the findings above to one of our principal consultants, or have the report rebuilt around the segments, geographies and competitors you actually track.
Market Segmentation
- By Product Type (Revenue, USD Bn, 2021-2033)
- Whole Blood
- Blood Components
- Red Blood Cells
- White Blood Cells
- Platelet
- Plasma
- By Application (Revenue, USD Bn, 2021-2033)
- Anemia
- Trauma and Surgery
- Cancer Treatment
- Bleeding Disorders
- Others (Others include rare blood diseases)
- By End User (Revenue, USD Bn, 2021-2033)
- Hospitals
- Ambulatory Surgical Centers
- Blood and Blood Component Bank
- Others
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- North America
Sources
Primary Research Interviews
- Blood Bank Directors
- Hospital Transfusion Medicine Specialists
- Hematologists and Oncologists
- Clinical Pathologists
- Blood Component Manufacturers
- Plasma Collection Center Operators
- Blood Bank Laboratory Managers
- Hospital Procurement Managers
- Transfusion Safety & Hemovigilance Experts
- Healthcare Regulatory Authorities
- Medical Device Manufacturers (Blood Processing & Screening)
- Others
Databases
- Bloomberg Terminal
- Thomson Reuters Eikon
- Factiva
- D&B Hoovers
- PitchBook
- Others
Magazines
- AABB News
- BloodBanking & Transfusion Medicine
- Medical Laboratory Observer (MLO)
- Healthcare Purchasing News
- Medical Device Network
- Healthcare Business Today
- Others
Journals
- Transfusion
- Blood
- Vox Sanguinis
- Transfusion Medicine
- Journal of Blood Medicine
- The Lancet Haematology
- Journal of Clinical Apheresis
- Others
Newspapers
- Reuters
- Bloomberg
- Financial Times
- The Wall Street Journal
- The New York Times
- The Economic Times
- Business Standard
- Others
Associations
- AABB (Association for the Advancement of Blood & Biotherapies)
- World Health Organization (WHO)
- International Society of Blood Transfusion (ISBT)
- European Blood Alliance (EBA)
- America's Blood Centers (ABC)
- International Plasma and Fractionation Association (IPFA)
- Plasma Protein Therapeutics Association (PPTA)
- Others
Public Domain Sources
- World Health Organization (WHO)
- U.S. Food and Drug Administration (FDA)
- Centers for Disease Control and Prevention (CDC)
- National Institutes of Health (NIH)
- American Red Cross
- National Health Commission of China (NHC)
- Ministry of Health & Family Welfare, Government of India
- eRaktKosh – National Blood Transfusion Council (NBTC)
- European Medicines Agency (EMA)
- Others
Proprietary Elements
- CMI Data Analytics Tool
- Proprietary CMI Existing Repository of Information for the Last 10 Years
Get access to 250+ pages report
Every segment, forecast, competitor profile and data table behind the analysis above — available for instant download.
- ESOMAR Member
- ISO 9001:2015 Certified
- D-U-N-S Registered
- GDPR & CCPA Compliant
Missing comfort of reading report in your local language? Find your preferred language:
Transform your Strategy with Exclusive Trending Reports
Frequently Asked Questions
The Blood and Blood Components Market is expected to reach USD 70.8 Bn by 2033.
Major players operating in the global Blood and Blood Components Market include Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc.
The shortage of voluntary blood donors and irregular blood supply, risk of transfusion-transmitted infections (TTIs), limited shelf life of blood components, and stringent regulatory requirements are the major factors hampering the growth of the market.
The rising prevalence of anemia and hematological disorders, increasing number of surgical procedures and trauma cases, growing demand for blood component therapy, expansion of voluntary blood donation programs, and increasing adoption of advanced blood screening technologies are driving the Blood and Blood Components Market.
The Blood and Blood Components Market is anticipated to grow at a CAGR of 4.7% between 2026 and 2033.
North America is expected to account for the largest share of the global Blood and Blood Components Market during the forecast period.
Blood components enable targeted transfusion therapy, allowing clinicians to administer red blood cells, plasma, platelets, or white blood cells based on individual patient needs. This approach improves blood utilization, reduces transfusion-related risks, and allows a single blood donation to benefit multiple patients.